A Phase 3 interventional study of rituximab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 53 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 22nd largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 28th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 52nd largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 81st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapies etanercept, infliximab or adalimumab therapy. All patients will receive infusions of 1000 mg intravenous (IV) MabThera on Days 1 and 15; at Week 24 patients who have demonstrated a moderate or good response will be randomized to receive re-treatment with either 1 or 2 additional infusions of 1000 mg IV MabThera. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1000 mg IV rituximab
Drug: rituximab
2 x 1000 mg IV rituximab
Drug: rituximab
Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
Also known as: MabThera/Rituxan
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104
DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter \[mg/L\]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and less than (\<)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)\*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the "true" DAS28-CRP value at the "true" Week 104).
Time frame: Week 104
DAS28-CRP During the Initial Treatment
Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
Time frame: Days 1 and 15, and Weeks 6, 12, and 24
DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
Time frame: Day 1, 24 weeks following each infusion up to 72 Weeks
Percentage of Participants Achieving Clinical Remission (DAS28-CRP <2.6) or Low Disease Activity (DAS28-CRP ≤3.2)
Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and \<2.6 = remission.
Time frame: Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
DAS28-CRP AUC Weighted Time
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Time to Achieve DAS28-CRP Remission After the First Course
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Time to Achieve DAS28-CRP Remission After Retreatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Time to Achieve DAS28-CRP ≤3.2 After Retreatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Duration of DAS28-CRP Remission After the First Course of Treatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Duration of DAS28-CRP Remission After Retreatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Duration of DAS28-CRP ≤3.2 After the First Course of Treatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Duration of DAS28-CRP ≤3.2 After Retreatment
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
Time frame: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)
ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale \[VAS\]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.
Time frame: Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.
Time frame: Day 15, Weeks 6, 12, and 24
Percentage of Participants Achieving a Response During Retreatment by EULAR Category
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.
Time frame: Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment
Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment
RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.
Time frame: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment
Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.
Time frame: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
Physician's Global Assessment of Disease Activity
The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Patient Global Assessment of Disease Activity
The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Patient's Global Assessment of Pain
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Participant Assessment of Fatigue
Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as "no fatigue" and the right-hand extreme equals 100 mm as "extreme fatigue". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Cortisone Intake AUC (Time- and Weight-Weighted)
All cortisone intakes (in mg) were taken into account (oral, IV \[including the cortisone administration before the rituximab infusion\], intramuscular, and intra-articular).
Time frame: Day 1 (each infusion), Week 24, Week 104
Total Mean Dose of Cortisone Between Week 24 and Week 104
All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.
Time frame: Week 24 to Week 104
HAQ-DI Scores
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Short Form 12 (SF-12) Physical Health Composite Score
Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
SF-12 Mental Health Composite Score
Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.
Time frame: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS
The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity
Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII
The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS
HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Percentage of Participants With MCII in Functioning
Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Change From Baseline in HAQ-DI in Participants With MCII
HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS
Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Higher values correspond to worst state of participant (high pain levels).
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Percentage of Participants With MCII in Pain
Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.
Time frame: Week 24, 12 and 24 weeks after 1st retreatment
Change From Baseline in Patient Global Assessment of Pain in Participants With MCII
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).
Time frame: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
| Milestone | Randomized Retreatment Arm A: Rituximab 1000 Milligrams (mg) | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | Nonrandomized: Rituximab 1000 mg |
|---|---|---|---|
| Started | 70 | 73 | 81 |
| Completed | 60 | 61 | 55 |
| Not completed | 10 | 12 | 26 |
| Withdrew: Adverse event | 0 | 2 | 4 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 6 | 1 | 11 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 5 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Administrative reason or other | 1 | 1 | 2 |
Mean DAS28-CRP at Week 24 of the Initial Treatment study. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-CRP ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
| units on a scale | Randomized Group | Nonrandomized Group |
|---|---|---|
| First Course, Day 1 | 5.82 ± 0.85 | 5.77 ± 0.90 |
| First Course, Day 15 | 5.33 ± 1.09 | 5.42 ± 1.07 |
| Follow-up, Week 6 | 4.69 ± 0.95 | 5.12 ± 1.05 |
| Follow-up, Week 12 | 4.13 ± 0.91 | 5.00 ± 1.19 |
| Follow-up, Week 24 | 3.65 ± 0.85 | 5.24 ± 1.08 |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=70,73) | 5.79 ± 0.85 | 5.84 ± 0.86 |
| Initial treatment, Week 24 (n=70,73) | 3.57 ± 0.89 | 3.73 ± 0.80 |
| Change at Week 24 (n=70,73) | -2.22 ± 0.96 | -2.11 ± 0.93 |
| 1st retreatment, Day 1 (n=66,68) | 4.33 ± 0.91 | 4.45 ± 0.80 |
| 1st retreatment, Week 24 (n=66,68) | 3.67 ± 1.15 | 3.69 ± 1.05 |
| 1st retreatment, Change at Week 24 (n=66,68) | -0.67 ± 1.15 | -0.79 ± 1.13 |
| 2nd retreatment, Day 1 (n=49,48) | 4.60 ± 0.87 | 4.55 ± 0.96 |
| 2nd retreatment, Week 24 (n=41,39) | 3.72 ± 1.10 | 3.76 ± 1.12 |
| 2nd retreatment, Change at Week 24 (n=41,39) | -0.94 ± 1.17 | -0.78 ± 1.07 |
DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter \[mg/L\]) at each visit. Joint counts included swollen joint count (SJC) and tender joint count (TJC). Total score range was 0 to 9.4; a higher score indicated more disease activity. DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and less than (\<)2.6 equals (=) remission. The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)\*((DAS28-CRP at t1 + DAS28-CRP at t2)/2). The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations. All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the "true" DAS28-CRP value at the "true" Week 104).
| score on a scale*week | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104 | 2761.4 ± 507.8 | 2666.0 ± 490.4 |
Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment. DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity and \<2.6 = remission.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Remission: Initial Treatment, Week 24 (n=70,73) | 14.3 | 8.2 |
| Remission: 1st Re-treatment, Week 24 (n=66,67) | 18.2 | 9.0 |
| Remission: 2nd Retreatment, Week 24 (n=43,40) | 16.3 | 7.5 |
| Low activity: Initial Treatment, Week 24 (n=70,73) | 37.1 | 27.4 |
| Low activity: 1st Retreatment, Week 24 (n=66,67) | 34.8 | 35.8 |
| Low activity: 2nd Retreatment, Week 24 (n=43,40) | 27.9 | 30.0 |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity, \>3.2 to 5.1 implied moderate to high disease activity, and \<2.6=remission.
| units on a scale*week | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| DAS28-CRP AUC Weighted Time | 3.82 ± 0.71 | 3.88 ± 0.71 |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
| weeks | Randomized Group |
|---|---|
| Time to Achieve DAS28-CRP Remission After the First Course | 56.0 (34.9 to NA) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
| weeks | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| 1st retreatment (n=66,68) | NA (NA to NA) | 78.1 (37.0 to NA) |
| 2nd retreatment (n=49,48) | NA (NA to NA) | NA (NA to NA) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
| weeks | Randomized Group |
|---|---|
| Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment | 28.0 (25.4 to NA) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
| weeks | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| 1st retreatment (n=66,68) | 31.0 (21.1 to NA) | 22.1 (14.1 to 47.9) |
| 2nd retreatment (n=49,48) | 16.9 (14.1 to 33.9) | 29.0 (15.0 to NA) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
| weeks | Randomized Group |
|---|---|
| Duration of DAS28-CRP Remission After the First Course of Treatment | 11.7 (8.0 to 15.1) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP \<2.6=remission.
| weeks | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| 1st retreatment (n=21,22) | 16.0 (15.0 to 17.0) | 8.0 (7.7 to 15.1) |
| 2nd retreatment (n=17,11) | 9.0 (8.0 to 16.3) | 8.0 (8.0 to 16.0) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
| weeks | Randomized Group |
|---|---|
| Duration of DAS28-CRP ≤3.2 After the First Course of Treatment | 14.3 (9.0 to 18.6) |
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit. Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L). Total score range=0 to 9.4; a higher score indicated more disease activity. A DAS28-CRP score of ≤3.2 implied low disease activity.
| weeks | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| 1st retreatment (n=35,40) | 27.0 (22.7 to 32.0) | 17.0 (9.0 to 28.0) |
| 2nd retreatment (n=29,23) | 10.1 (8.0 to 32.1) | 16.0 (9.0 to 31.1) |
ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale \[VAS\]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| ACR20: Initial Treatment, Week 24 | 78.6 | 75.3 |
| ACR20: 1st Retreatment, Week 24 | 63.6 | 61.2 |
| ACR20: 2nd Retreatment, Week 24 | 65.1 | 60.0 |
| ACR50: Initial Treatment, Week 24 | 35.7 | 32.9 |
| ACR50: 1st Retreatment, Week 24 | 33.3 | 32.8 |
| ACR50: 2nd Retreatment, Week 24 | 32.6 | 42.5 |
| ACR70: Initial Treatment, Week 24 | 12.9 | 11.0 |
| ACR70: 1st Retreatment, Week 24 | 16.7 | 19.4 |
| ACR70: 2nd Retreatment, Week 24 | 18.6 | 20.0 |
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.
| percentage of participants | Randomized Group | Nonrandomized Group |
|---|---|---|
| Good response: Day 15 | 4 | 3 |
| Good response: Week 6 | 5 | 4 |
| Good response: Week 12 | 15 | 4 |
| Good response: Week 24 | 32 | 3 |
| Moderate response: Day 15 | 22 | 20 |
| Moderate response: Week 6 | 59 | 29 |
| Moderate response: Week 12 | 73 | 35 |
| Moderate response: Week 24 | 66 | 15 |
| No response: Day 15 | 74 | 78 |
| No response: Week 6 | 36 | 67 |
| No response: Week 12 | 11 | 61 |
| No response: Week 24 | 3 | 82 |
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders = change from baseline \>1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤ 5.1 or change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline \>0.6 and ≤ 1.2 with a DAS28 score of \>5.1.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Good response: Week 24 (n=70,73) | 37 | 26 |
| Good response: 1st retreatment (n=66,67) | 35 | 36 |
| Good response: 2nd retreatment (n=43,40) | 28 | 30 |
| Moderate response: Week 24 (n=70,73) | 60 | 71 |
| Moderate response: 1st retreatment (n=66,67) | 53 | 52 |
| Moderate response: 2nd retreatment (n=43,40) | 54 | 50 |
| No response: Week 24 (n=70,73) | 3 | 3 |
| No response: 1st retreatment (n=66,67) | 12 | 12 |
| No response: 2nd retreatment (n=43,40) | 19 | 20 |
RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 international units per milliliter (IU/mL) is considered positive.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Negative: Initial treatment, Week 24 (n=69,71) | 33.3 ± 273.09 | 38.0 ± 408.24 |
| Positive: Initial treatment, Week 24 (n=69,71) | 66.7 ± 114.63 | 62.0 ± 386.02 |
| Negative: 1st Retreatment, Week 24 (n=44,43) | 36.4 ± 79.14 | 48.8 ± 65.29 |
| Positive: 1st Retreatment, Week 24 (n=44,43) | 63.6 ± 75.68 | 51.2 ± 41.01 |
| Negative: 2nd retreatment, Week 24 (n=15,12) | 46.7 | 83.3 |
| Positive: 2nd retreatment, Week 24 (n=15,12) | 53.3 | 16.7 |
Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Negative: Initial treatment, Week 24 (n=69,71) | 17.4 | 22.5 |
| Positive: Initial treatment, Week 24 (n=69,71) | 82.6 | 77.5 |
| Negative: 1st Retreatment, Week 24 (n=44,43) | 22.7 | 20.9 |
| Positive: 1st Retreatment, Week 24 (n=44,43) | 77.3 | 79.1 |
| Negative: 2nd retreatment, Week 24 (n=15,12) | 13.3 | 41.7 |
| Positive: 2nd retreatment, Week 24 (n=15,12) | 86.7 | 58.3 |
The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Physicians were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high disease activity).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=70,73) | 65.0 ± 15.0 | 64.1 ± 15.0 |
| Initial treatment, Week 24 (n=69,71) | 27.9 ± 18.6 | 27.2 ± 16.2 |
| Before 1st retreatment (n=64,63) | 33.7 ± 17.4 | 26.9 ± 17.1 |
| 1st retreatment, Day 1 (n=60,61) | 44.4 ± 20.8 | 43.3 ± 18.5 |
| 1st retreatment, Week 12 (n=56,62) | 30.4 ± 18.8 | 28.4 ± 18.0 |
| 1st retreatment, Week 24 (n=60,59) | 31.9 ± 19.1 | 24.8 ± 16.3 |
The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
| mm | Randomized Re-treatment Arm A: Single 1000 mg IV Rituximab | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=70,73) | 63.0 ± 20.4 | 64.2 ± 18.0 |
| Initial treatment, Week 24 (n=70,73) | 29.9 ± 22.3 | 32.6 ± 22.7 |
| Before 1st retreatment (n=65,67) | 33.2 ± 19.6 | 34.7 ± 22.3 |
| 1st retreatment, Day 1 (n=65,66) | 43.7 ± 21.2 | 46.6 ± 21.3 |
| 1st retreatment, Week 12 (n=63,65) | 34.8 ± 21.2 | 34.5 ± 25.3 |
| 1st retreatment, Week 24 (n=64,60) | 35.1 ± 24.6 | 34.1 ± 23.1 |
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial Treatment, Day 1 (n=70,73) | 61.9 ± 22.3 | 60.1 ± 19.9 |
| Initial Treatment, Week 24 (n=70,73) | 28.5 ± 22.0 | 30.0 ± 21.7 |
| Before 1st retreatment (n=65,67) | 34.4 ± 21.3 | 32.9 ± 23.0 |
| 1st re-treatment, Day 1 (n=65,67) | 41.1 ± 21.5 | 45.2 ± 22.4 |
| 1st retreatment, Week 12 (n=64,60) | 34.3 ± 21.4 | 33.9 ± 25.6 |
| 1st retreatment, Week 24 (n=64,60) | 34.4 ± 24.6 | 34.3 ± 23.7 |
Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS. The left-hand extreme of the line equals 0 mm, and is described as "no fatigue" and the right-hand extreme equals 100 mm as "extreme fatigue". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high levels of fatigue).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial Treatment, Day 1 (n=70,73) | 62.1 ± 21.4 | 62.0 ± 22.5 |
| Initial Treatment, Week 24 (n=70,73) | 37.1 ± 24.2 | 39.8 ± 25.8 |
| Before 1st retreatment (n=64,66) | 44.5 ± 20.8 | 41.2 ± 26.1 |
| 1st retreatment, Day 1 (n=65,64) | 50.6 ± 22.6 | 51.7 ± 21.6 |
| 1st retreatment, Week 12 (n=63,65) | 45.2 ± 23.0 | 45.3 ± 25.5 |
| 1st retreatment, Week 24 (n=64,60) | 43.0 ± 25.3 | 38.9 ± 23.6 |
All cortisone intakes (in mg) were taken into account (oral, IV \[including the cortisone administration before the rituximab infusion\], intramuscular, and intra-articular).
| mg*week | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Day 1 to Week 104 (n=69,73) | 0.08 ± 0.06 | 0.09 ± 0.06 |
| 1st retreatment to Week 104 (n=65,68) | 0.08 ± 0.06 | 0.09 ± 0.06 |
| Week 24 to Week 104 (n=69,73) | 0.08 ± 0.06 | 0.09 ± 0.06 |
All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.
| mg | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Total cortisone: Week 24 to Week 104 | 2542.9 ± 2085.6 | 2842.5 ± 2124.9 |
| Oral cortisone: Week 24 to Week 104 | 2384.0 ± 2092.6 | 2425.1 ± 2046.6 |
| IV cortisone: Week 24 to Week 104 | 199.1 ± 92.3 | 384.9 ± 193.5 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=70,69) | 1.74 ± 0.61 | 1.75 ± 0.69 |
| Initial treatment, Week 24 (n=68,72) | 1.25 ± 0.67 | 1.31 ± 0.74 |
| Before 1st retreatment (n=64,67) | 1.26 ± 0.67 | 1.35 ± 0.73 |
| 1st retreatment, Day 1 (n=58,58) | 1.32 ± 0.68 | 1.42 ± 0.73 |
| 1st retreatment, Week 12 (n=62,61) | 1.31 ± 0.66 | 1.33 ± 0.72 |
| 1st retreatment, Week 24 (n=63,59) | 1.26 ± 0.72 | 1.32 ± 0.72 |
Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=62,65) | 31.11 ± 7.55 | 31.07 ± 7.41 |
| Initial Tteatment, Week 24 (n=63,68) | 38.81 ± 8.39 | 40.05 ± 8.64 |
| Before 1st retreatment (n=21,22) | 39.44 ± 8.45 | 39.52 ± 9.99 |
| 1st retreatment, Day 1 (n=47,44) | 36.57 ± 6.75 | 35.81 ± 8.97 |
| 1st retreatment, Week 12 (n=13,10) | 38.36 ± 9.30 | 38.05 ± 10.77 |
| 1st retreatment, Week 24 (n=40,36) | 36.53 ± 7.75 | 36.86 ± 8.13 |
Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=62,65) | 36.03 ± 10.03 | 37.13 ± 9.40 |
| Initial treatment, Week 24 (n=63,68) | 43.08 ± 9.74 | 40.99 ± 9.01 |
| Before 1st retreatment (n=21,22) | 44.94 ± 9.94 | 41.57 ± 8.66 |
| 1st retreatment, Day 1 (n=47,44) | 40.87 ± 10.53 | 38.52 ± 7.87 |
| 1st retreatment, Week 12 (n=13,10) | 41.84 ± 11.36 | 34.69 ± 11.06 |
| 1st retreatment, Week 24 (n=40,36) | 40.90 ± 10.61 | 41.60 ± 8.87 |
The MOS Sleep Scale measures most constructs of sleep. The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities. The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains. The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Initial treatment, Day 1 (n=68,66) | 52.15 ± 15.32 | 49.89 ± 15.81 |
| Initial treatment, Week 24 (n=65,70) | 43.73 ± 14.90 | 40.50 ± 17.17 |
| Before 1st retreatment (n=62,65) | 45.44 ± 13.97 | 41.27 ± 17.01 |
| 1st retreatment, Day 1 (n=57,56) | 46.25 ± 16.53 | 44.94 ± 16.02 |
| 1st retreatment, Week 12 (n=61,59) | 43.64 ± 14.41 | 43.74 ± 18.60 |
| 1st retreatment, Week 24 (n=63,59) | 44.74 ± 15.35 | 40.08 ± 16.76 |
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 | 73.4 | 75.4 |
| 1st retreatment, Week 12 | 73.3 | 62.5 |
| 1st retreatment, Week 24 | 70.5 | 64.3 |
The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=47,52) | 23.4 ± 18.5 | 28.4 ± 19.1 |
| 1st retreatment, Week 12 (n=44,35) | 27.4 ± 16.6 | 27.3 ± 21.8 |
| 1st retreatment, Week 24 (n=43,36) | 26.3 ± 19.5 | 25.7 ± 16.4 |
Participants were asked how their disease activity had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 | 75.4 | 81.2 |
| 1st retreatment, Week 12 | 65.6 | 63.0 |
| 1st retreatment, Week 24 | 66.7 | 66.1 |
The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=49,56) | -12.4 ± 20.7 | -4.6 ± 22.9 |
| 1st retreatment, Week 12 (n=38,30) | -4.2 ± 16.0 | -9.2 ± 17.7 |
| 1st retreatment, Week 24 (n=40,37) | -2.5 ± 17.8 | -2.9 ± 20.6 |
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 | 74.2 | 72.7 |
| 1st retreatment, Week 12 | 75.9 | 60.0 |
| 1st retreatment, Week 24 | 70.2 | 62.1 |
HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours). HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=46,48) | 1.16 ± 0.69 | 1.16 ± 0.74 |
| 1st retreatment, Week 12 (n=44,33) | 1.20 ± 0.70 | 1.08 ± 0.71 |
| 1st retreatment, Week 24 (n=40,36) | 1.14 ± 0.75 | 1.08 ± 0.72 |
Participants were asked how their functioning had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 | 73.4 | 76.5 |
| 1st retreatment, Week 12 | 65.0 | 63.0 |
| 1st retreatment, Week 24 | 65.5 | 57.9 |
HAQ-DI was assessed in participants with MCII. HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
| units on a scale | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=47,52) | -0.11 ± 0.46 | -0.06 ± 0.56 |
| 1st retreatment, Week 12 (n=38,30) | -0.03 ± 0.30 | -0.11 ± 0.39 |
| 1st retreatment, Week 24 (n=38,30) | -0.07 ± 0.24 | -0.09 ± 0.29 |
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours. In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 | 74.2 | 75.0 |
| 1st retreatment Week 12 | 70.2 | 61.8 |
| 1st retreatment, Week 24 | 72.9 | 61.4 |
Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Higher values correspond to worst state of participant (high pain levels).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=46,51) | 21.5 ± 16.2 | 26.4 ± 18.5 |
| 1st retreatment, Week 12 (n=40,34) | 26.8 ± 17.3 | 27.6 ± 22.4 |
| 1st retreatment, Week 24 (n=43,35) | 26.3 ± 20.1 | 25.1 ± 17.3 |
Participants were asked how their pain had been during the last 48 hours compared to baseline. Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important. Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.
| percentage of participants | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=63,70) | 76.2 | 80.0 |
| 1st retreatment, Week 12 (n=59,55) | 71.2 | 69.1 |
| 1st retreatment, Week 24 (n=61,57) | 68.9 | 61.4 |
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". Participants were asked to mark the line and the distance from the left edge was measured. Higher values correspond to worst state of participant (high pain levels).
| mm | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 |
|---|---|---|
| Week 24 (n=48,56) | -13.5 ± 21.0 | -4.3 ± 23.9 |
| 1st retreatment, Week 12 (n=39,35) | -2.7 ± 13.6 | -8.9 ± 16.4 |
| 1st retreatment, Week 24 (n=42,35) | -3.5 ± 24.3 | -3.2 ± 18.4 |
Collected over Baseline to 104 weeks; related serious adverse events (SAEs) were collected and reported regardless of time elapsed from last dose of study drug; unrelated SAEs were collected during the study and for up to 24 weeks after last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Retreatment Arm A: Rituximab 1000 mg | — | 19/66 (28.8%) | 61/66 (92.4%) |
| Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | — | 25/68 (36.8%) | 65/68 (95.6%) |
| Nonrandomized: Rituximab 1000 mg | — | 16/81 (19.8%) | 72/81 (88.9%) |
| Event | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | Nonrandomized: Rituximab 1000 mg |
|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/66 | 4/68 | 2/81 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/66 | 2/68 | 1/81 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/66 | 2/68 | 1/81 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/66 | 0/68 | 2/81 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/66 | 1/68 | 0/81 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/66 | 0/68 | 0/81 |
| Rheumatoid noduleMusculoskeletal and connective tissue disorders | 1/66 | 0/68 | 0/81 |
| Abdominal wall abscessInfections and infestations | 1/66 | 0/68 | 0/81 |
| Bursitis infectiveInfections and infestations | 1/66 | 0/68 | 0/81 |
| CellulitisInfections and infestations | 1/66 | 0/68 | 0/81 |
| Event | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | Nonrandomized: Rituximab 1000 mg |
|---|---|---|---|
| BronchitisInfections and infestations | 13/66 | 16/68 | 11/81 |
| Urinary tract infectionInfections and infestations | 9/66 | 12/68 | 14/81 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 8/66 | 12/68 | 8/81 |
| AstheniaGeneral disorders | 11/66 | 11/68 | 6/81 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/66 | 4/68 | 3/81 |
| HeadacheNervous system disorders | 7/66 | 11/68 | 10/81 |
| Back painMusculoskeletal and connective tissue disorders | 10/66 | 10/68 | 3/81 |
| GastroenteritisInfections and infestations | 8/66 | 10/68 | 3/81 |
| NasopharyngitisInfections and infestations | 7/66 | 6/68 | 2/81 |
| NauseaGastrointestinal disorders | 7/66 | 5/68 | 6/81 |
| Age, Continuous(years) | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | Nonrandomized: Rituximab 1000 mg | Total |
|---|---|---|---|---|
| Mean | 54.5 ± 11.5 | 57.2 ± 10.4 | 56.1 ± 11.2 | 56.0 ± 11.0 |
| Sex: Female, Male(Participants) | Randomized Retreatment Arm A: Rituximab 1000 mg | Randomized Retreatment Arm B: Rituximab 1000 mg x 2 | Nonrandomized: Rituximab 1000 mg | Total |
|---|---|---|---|---|
| Female | 55 | 62 | 70 | 187 |
| Male | 15 | 11 | 11 | 37 |
The record gives a start of Sep 2006, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab